September 16, 2020 -- Ashion Analytics has partnered with Elevation Oncology to match patients harboring an NRG1 gene fusion identified with Ashion's Gem Extra test with a phase II clinical study of seribantumab, an investigational monoclonal antibody treatment for advanced solid tumors.
NRG1 gene fusions are a rare genomic alteration that drives tumor development and growth in many types of solid tumors including lung, breast, pancreatic, ovarian, and colorectal cancers. Crestone, a clinical trial evaluating seribantumab in tumors with NRG1 fusions sponsored by Elevation, is an investigational treatment option for patients with advanced solid tumors that have not responded to standard cancer treatments, and whose tumor has tested positive for the NRG1 fusion.
In the partnership, Ashion Analytics will leverage its technology platform to efficiently identify and directly match eligible patients to the Crestone trial using test results that are already available, namely Ashion's Gem Extra test. The test detects tumor-specific mutations in both DNA and RNA and enables physicians to make the best-available treatment recommendations for patients with advanced solid tumors.
Ashion Analytics is a clinical laboratory of the Translational Genomics Research Institute, an affiliate of City of Hope.